Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) TSE: AUP COO Matthew Maxwell Donley sold 65,902 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $527,216.00. Following the completion of the sale, the chief operating officer now directly owns 739,456 shares of the company's stock, valued at approximately $5,915,648. This represents a 8.18 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Aurinia Pharmaceuticals Trading Down 0.5 %
Aurinia Pharmaceuticals stock traded down $0.04 during midday trading on Friday, reaching $8.15. The stock had a trading volume of 1,152,887 shares, compared to its average volume of 1,481,486. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.67. The stock has a market capitalization of $1.17 billion, a PE ratio of -54.33 and a beta of 1.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock's 50-day simple moving average is $8.08 and its 200 day simple moving average is $7.87.
Analysts Set New Price Targets
Separately, StockNews.com downgraded Aurinia Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, February 19th.
Get Our Latest Research Report on Aurinia Pharmaceuticals
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AUPH. Tang Capital Management LLC boosted its holdings in Aurinia Pharmaceuticals by 16.6% in the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company's stock valued at $75,697,000 after acquiring an additional 1,200,000 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $9,662,000. Point72 Asset Management L.P. acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $7,630,000. Lazard Asset Management LLC lifted its stake in shares of Aurinia Pharmaceuticals by 341.9% during the fourth quarter. Lazard Asset Management LLC now owns 596,389 shares of the biotechnology company's stock worth $5,355,000 after purchasing an additional 461,430 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Aurinia Pharmaceuticals during the third quarter worth about $3,330,000. Institutional investors and hedge funds own 36.83% of the company's stock.
About Aurinia Pharmaceuticals
(
Get Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
See Also
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
